| Literature DB >> 33499061 |
Markéta Kovářová1,2,3, Hubert Kalbacher4, Andreas Peter1,2,3, Hans-Ulrich Häring2,5, Triantafyllos Didangelos6, Norbert Stefan2,3,5, Andreas Birkenfeld2,3,5, Erwin Schleicher1,2,3, Konstantinos Kantartzis2,3,5.
Abstract
The hepatokine fetuin A (Fet A) has been associated with diverse pathological states such as insulin resistance, type 2 diabetes, macrovascular disease, and systemic ectopic and vascular calcification. Fet A may also play a role in tumor growth and metastasis. The biological activity of Fet A may be affected by various modifications, including phosphorylation, O- and N-glycosylation and fatty acid binding. We developed an antibody-based assay for the detection of Fet A phosphorylated at serine 312. Fatty acid pattern was determined by gas chromatography. Using the antibody, we found that the phosphorylation was stable in human plasma or serum at room temperature for 8 h. We observed that Fet A is present in several glycosylation forms in human plasma, but the extent of Ser312 phosphorylation was not associated with glycosylation. The phosphorylation pattern did not change during an oral glucose tolerance test (0-120 min). We further found that human Fet A binds preferentially saturated fatty acids (>90%) at the expense of mono- and poly-unsaturated fatty acids. Our results indicate that different molecular species of Fet A are present in human plasma and that these different modifications may determine the different biological effects of Fet A.Entities:
Keywords: FAM20C; fatty acid bound to fetuin A; fatty liver; fetuin A; glycosylation; obesity; phosphorylation
Year: 2021 PMID: 33499061 PMCID: PMC7865524 DOI: 10.3390/jcm10030411
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241